Kintz Samuel, President and CEO of Enliven Therapeutics ($ELVN), sold about $2.3 million in company shares across 20 open market transactions over the past year. His most recent sale occurred on November 17, 2025. These sales rank 3,194th among 11,678 individual insiders in our database, where the average is about $8.6 million per seller over roughly 6.4 trades. Samuel made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12500 | $21.82 | 890,392.0000 | 62,093,795 | 1.38% | 0.02% |
| Oct. 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12500 | $21.33 | 902,892.0000 | 62,093,795 | 1.37% | 0.02% |
| Sept. 26, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 3700 | $20.06 | 915,392.0000 | 47,072,532 | 0.40% | 0.01% |
| Sept. 23, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 2800 | $20.03 | 919,092.0000 | 47,072,532 | 0.30% | 0.01% |
| Sept. 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 5000 | $19.09 | 922,892.0000 | 47,072,532 | 0.54% | 0.01% |
| Sept. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 1000 | $20.25 | 921,892.0000 | 47,072,532 | 0.11% | 0.00% |
| Aug. 20, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 1517 | $20.00 | 927,892.0000 | 47,072,532 | 0.16% | 0.00% |
| Aug. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 590 | $20.00 | 929,409.0000 | 47,072,532 | 0.06% | 0.00% |
| Aug. 18, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 10393 | $20.02 | 929,999.0000 | 47,072,532 | 1.11% | 0.02% |
| July 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 4687 | $22.69 | 944,055.0000 | 47,072,532 | 0.49% | 0.01% |
| July 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 3663 | $23.37 | 940,392.0000 | 47,072,532 | 0.39% | 0.01% |
| July 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 4150 | $21.58 | 948,742.0000 | 47,072,532 | 0.44% | 0.01% |
| June 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 1998 | $22.75 | 952,892.0000 | 47,072,532 | 0.21% | 0.00% |
| June 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 10502 | $22.08 | 954,890.0000 | 47,072,532 | 1.09% | 0.02% |
| June 3, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 7500 | $20.05 | 965,392.0000 | 47,072,532 | 0.77% | 0.02% |
| May 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 5000 | $16.49 | 972,892.0000 | 47,072,532 | 0.51% | 0.01% |
| May 1, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 5330 | $20.08 | 980,062.0000 | 47,072,532 | 0.54% | 0.01% |
| May 2, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 2170 | $20.00 | 977,892.0000 | 47,072,532 | 0.22% | 0.00% |
| April 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 5000 | $16.42 | 985,392.0000 | 47,072,532 | 0.50% | 0.01% |
| March 17, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12500 | $20.83 | 990,392.0000 | 47,072,532 | 1.25% | 0.03% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | A | Stock Option (right to buy) | 490000 | $0.00 | 490,000.0000 | 47,072,532 | 9999.99% | 1.04% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 924 | $30.00 | 1,002,892.0000 | 48,267,458 | 0.09% | 0.00% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 100 | $28.51 | 1,020,526.0000 | 48,267,458 | 0.01% | 0.00% |
| Oct. 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 13880 | $28.07 | 1,006,646.0000 | 48,267,458 | 1.36% | 0.03% |
| Oct. 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 2830 | $28.53 | 1,003,816.0000 | 48,267,458 | 0.28% | 0.01% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 13167 | $27.95 | 1,020,626.0000 | 48,267,458 | 1.27% | 0.03% |
| Oct. 7, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 2730 | $27.50 | 1,033,793.0000 | 48,267,458 | 0.26% | 0.01% |
| Oct. 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12206 | $27.51 | 1,036,523.0000 | 48,267,458 | 1.16% | 0.03% |
| Oct. 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 526 | $27.54 | 1,048,729.0000 | 48,267,458 | 0.05% | 0.00% |
| Aug. 26, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12000 | $22.89 | 1,049,255.0000 | 35,546,215 | 1.13% | 0.03% |
| July 31, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 2270 | $27.56 | 1,061,255.0000 | 35,546,215 | 0.21% | 0.01% |
| July 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 43 | $25.83 | 1,240,587.0000 | 35,546,215 | 0.00% | 0.00% |
| July 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 8164 | $25.10 | 1,240,630.0000 | 35,546,215 | 0.65% | 0.02% |
| July 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 3793 | $24.53 | 1,248,794.0000 | 35,546,215 | 0.30% | 0.01% |
| June 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 578 | $22.30 | 1,252,587.0000 | 35,546,215 | 0.05% | 0.00% |
| June 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 11422 | $21.63 | 1,253,165.0000 | 35,546,215 | 0.90% | 0.03% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 188,841.0000 | 35,546,215 | 5.97% | 0.03% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 35,546,215 | 0.95% | 0.03% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 6681 | $22.86 | 1,269,906.0000 | 35,546,215 | 0.52% | 0.02% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 5219 | $23.57 | 1,264,687.0000 | 35,546,215 | 0.41% | 0.01% |
| May 28, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 100 | $24.34 | 1,264,587.0000 | 35,546,215 | 0.01% | 0.00% |
| April 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 200,841.0000 | 35,546,215 | 5.64% | 0.03% |
| April 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 35,546,215 | 0.95% | 0.03% |
| April 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 12000 | $16.89 | 1,264,587.0000 | 35,546,215 | 0.94% | 0.03% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Stock Option (right to buy) | 47709 | $0.00 | 212,841.0000 | 35,546,215 | 18.31% | 0.13% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Common Stock | 47709 | $1.12 | 1,312,296.0000 | 35,546,215 | 3.77% | 0.13% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 47709 | $25.04 | 1,264,587.0000 | 35,546,215 | 3.64% | 0.13% |
| March 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 4671 | $18.16 | 1,264,587.0000 | 35,546,215 | 0.37% | 0.01% |
| March 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 7329 | $17.17 | 1,269,258.0000 | 35,546,215 | 0.57% | 0.02% |
| March 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 35,546,215 | 0.95% | 0.03% |
| March 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 260,550.0000 | 35,546,215 | 4.40% | 0.03% |
| Feb. 26, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 4376 | $17.24 | 1,264,587.0000 | 35,546,215 | 0.34% | 0.01% |
| Feb. 26, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | S | Common Stock | 7624 | $16.69 | 1,268,963.0000 | 35,546,215 | 0.60% | 0.02% |
| Feb. 26, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 35,546,215 | 0.95% | 0.03% |
| Feb. 26, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 272,550.0000 | 35,546,215 | 4.22% | 0.03% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | PRESIDENT AND CEO | A | Stock Option (right to buy) | 410000 | $0.00 | 410,000.0000 | 35,546,215 | 9999.99% | 1.15% |
| Jan. 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 9458 | $15.89 | 1,264,587.0000 | 35,546,215 | 0.74% | 0.03% |
| Jan. 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 35,546,215 | 0.95% | 0.03% |
| Jan. 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 2542 | $14.94 | 1,274,045.0000 | 35,546,215 | 0.20% | 0.01% |
| Jan. 25, 2024 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 284,550.0000 | 35,546,215 | 4.05% | 0.03% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 296,550.0000 | 0 | 3.89% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 0 | 0.95% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 12000 | $14.64 | 1,264,587.0000 | 0 | 0.94% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 20 | $13.00 | 1,264,587.0000 | 0 | 0.00% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 20 | $1.12 | 1,264,607.0000 | 0 | 0.00% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 8175 | $1.12 | 1,272,762.0000 | 0 | 0.65% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 8175 | $13.05 | 1,264,587.0000 | 0 | 0.64% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 20 | $0.00 | 316,725.0000 | 0 | 0.01% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 8175 | $0.00 | 308,550.0000 | 0 | 2.58% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 7779 | $0.00 | 316,745.0000 | 0 | 2.40% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 7779 | $13.01 | 1,264,587.0000 | 0 | 0.61% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 7779 | $1.12 | 1,272,366.0000 | 0 | 0.62% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 8026 | $0.00 | 324,524.0000 | 0 | 2.41% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 8026 | $1.12 | 1,272,613.0000 | 0 | 0.63% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 8026 | $13.08 | 1,264,587.0000 | 0 | 0.63% | 0.00% |
| Sept. 25, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Stock Option (right to buy) | 12000 | $0.00 | 332,550.0000 | 0 | 3.48% | 0.00% |
| Sept. 25, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | M | Common Stock | 12000 | $1.12 | 1,276,587.0000 | 0 | 0.95% | 0.00% |
| Sept. 25, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | S | Common Stock | 12000 | $13.81 | 1,264,587.0000 | 0 | 0.94% | 0.00% |
| April 4, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Stock Option (right to buy) | 452000 | $0.00 | 452,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Common Stock | 88531 | $0.00 | 88,531.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Common Stock | 88531 | $0.00 | 88,531.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Employee Stock Option (right to buy) | 344550 | $0.00 | 344,550.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Employee Stock Option (right to buy) | 404363 | $0.00 | 404,363.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Kintz Samuel | President and CEO | A | Common Stock | 1087525 | $0.00 | 1,087,525.0000 | 0 | 9999.99% | 0.00% |